<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR26">
 <label>26.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Revuelta-Herrero</surname>
    <given-names>JL</given-names>
   </name>
   <name>
    <surname>Chamorro-de-Vega</surname>
    <given-names>E</given-names>
   </name>
   <name>
    <surname>Rodríguez-González</surname>
    <given-names>CG</given-names>
   </name>
   <name>
    <surname>Alonso</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Herranz-Alonso</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Sanjurjo-Sáez</surname>
    <given-names>M</given-names>
   </name>
  </person-group>
  <article-title>Effectiveness, safety, and costs of a treatment switch to dolutegravir plus rilpivirine dual therapy in treatment-experienced HIV patients</article-title>
  <source>Ann Pharmacother</source>
  <year>2018</year>
  <volume>52</volume>
  <fpage>11</fpage>
  <lpage>18</lpage>
  <?supplied-pmid 28836468?>
  <pub-id pub-id-type="pmid">28836468</pub-id>
 </element-citation>
</ref>
